SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 4/26/24 Bio-Rad Laboratories, Inc. 8-K:5,7,9 4/22/24 13:477K |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 60K 2: EX-10.1 Material Contract HTML 210K 3: EX-99.1 Miscellaneous Exhibit HTML 10K 8: R1 Document and Entity Information Document HTML 50K 10: XML IDEA XML File -- Filing Summary XML 12K 13: XML XBRL Instance -- bio-20240422_htm XML 18K 9: EXCEL IDEA Workbook of Financial Report Info XLSX 8K 5: EX-101.DEF XBRL Definitions -- bio-20240422_def XML 40K 6: EX-101.LAB XBRL Labels -- bio-20240422_lab XML 77K 7: EX-101.PRE XBRL Presentations -- bio-20240422_pre XML 41K 4: EX-101.SCH XBRL Schema -- bio-20240422 XSD 12K 11: JSON XBRL Instance as JSON Data -- MetaLinks 14± 21K 12: ZIP XBRL Zipped Folder -- 0000012208-24-000031-xbrl Zip 64K
bio-20240422 |
i Delaware | i 94-1381833 | |||||||
(State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | |||||
i ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||
i ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||
i ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||
i ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: | ||||||||||||||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
i Class A Common Stock, Par Value $0.0001 per share | i BIO | i New York Stock Exchange | ||||||||||||
i Class B Common Stock, Par Value $0.0001 per share | i BIO.B | i New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
Emerging growth company | i ☐ | |||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ |
1.
Each of the nominated directors was elected and received the affirmative vote of a majority of the votes cast in the respective class of Common Stock, as follows: | |||||||||||||||||||||||
Class of Common Stock | Votes | Votes | Votes | Broker | |||||||||||||||||||
to Elect | For | Against | Abstaining | Non-Votes | |||||||||||||||||||
Melinda Litherland | Class A | 17,178,561 | 2,491,017 | 8,267 | 1,944,423 | ||||||||||||||||||
Arnold A. Pinkston | Class A | 17,412,897 | 2,255,866 | 9,082 | 1,944,423 | ||||||||||||||||||
Jeffrey L. Edwards | Class B | 4,992,038 | 325 | 1 | 51,564 | ||||||||||||||||||
Gregory K. Hinckley | Class B | 4,991,949 | 325 | 90 | 51,564 | ||||||||||||||||||
Allison Schwartz | Class B | 4,990,900 | 1,374 | 90 | 51,564 | ||||||||||||||||||
Norman Schwartz | Class B | 4,990,900 | 1,374 | 90 | 51,564 | ||||||||||||||||||
2. The proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2024 was ratified and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: | |||||||||||||||||||||||
Votes | Votes | Votes | Broker | ||||||||||||||||||||
For | Against | Abstaining | Non-Votes | ||||||||||||||||||||
7,151,808 | 51,181 | 3,166 | - | ||||||||||||||||||||
3. The proposal to approve the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan, as amended was approved and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: | |||||||||||||||||||||||
Votes | Votes | Votes | Broker | ||||||||||||||||||||
For | Against | Abstaining | Non-Votes | ||||||||||||||||||||
6,870,787 | 84,984 | 4,378 | 246,006 |
Exhibit
Number | Description | |||||||
10.1 | ||||||||
99.1 | ||||||||
104.1 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document |
BIO-RAD LABORATORIES, INC. | ||||||||||||||
Date: | April 26, 2024 | By: | /s/ Courtney C. Enloe | |||||||||||
Courtney C. Enloe | ||||||||||||||
EVP, General Counsel and Secretary |
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
2/9/34 | ||||
12/31/24 | ||||
5/1/24 | ||||
Filed on: | 4/26/24 | |||
4/24/24 | ||||
4/23/24 | DEF 14A | |||
For Period end: | 4/22/24 | SC 13G | ||
3/27/24 | ARS, DEF 14A | |||
9/18/23 | ||||
8/25/23 | 4, 8-K | |||
List all Filings |